Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer

Medical Oncology

Volumn 16, Issue 1, 1999, Pages 17-22

  Krüger, William ^a   Tögel, Florian ^a   Kröger, Nicolaus ^a   Rössing, Sabine ^a   Gieseking, Friederike ^a   Gutensohn, K ^a   Lindner, Christoph ^a   Jänicke, Fritz ^a   Zander, Axel R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Blood stem cells; Breast cancer; High dose therapy; Micrometastases; Tumour cells

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER TRANSPLANTATION; CELL COUNT; CONTAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEMATOPOIESIS; HUMAN; IMMUNOCYTOCHEMISTRY; LEUKAPHERESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR CELL;

EID: 0033042541     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02787354     Document Type: Article

References (21)

1. Gradishar WJ. Inflammatory breast cancer: the evolution of multimodality treatment strategies. Semin Surg Oncol 1996; 12(5): 352-363.
2. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994; 74(1 Suppl.): 416-423.
3. Weidner N. Prognostic factors in breast carcinoma. Curr Opin Obstet Gynecol 1995; 7(1): 4-9.
4. Peters WP et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11(6): 1132-1143.
5. Zander AR et al. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study. Bone Marrow Transplant 1996; 18 (Suppl. 1): S24-S25.
6. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13(10): 2483-2489.
7. Nitz U et al. [Significance of stem cell-supported high-dose chemotherapy in the treatment of gynecological malignancies: indications and current clinical trials in the Federal Republic of Germany]. Zentralbl Gynakol 1997; 119(5): 195-203.
8. Fields KK, Elfenbein GJ, Perkins JB, Moscinski LC. High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts. Ann NY Acad Sci 1995; 770: 288-304.
9. Datta YH et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12(3): 475-482.
10. Brugger W et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83(3): 636-640.
11. Ross AA et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82(9): 2605-2610.
12. Diel IJ et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992; 10(10): 1534-1539.
13. Schulze R et al. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients. Bone Marrow Transplant 1997; 19(12): 1223-1228.
14. Passos-Coelho JL et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1995; 85(4): 1138-1143.
15. Passos-Coelho JL et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996; 14(9): 2569-2575.
16. Schlimok G et al. Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 1990; 8(5): 831-837.
17. Krüger W et al. Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J Cancer Res Clin Oncol 1996; 122(11): 679-686.
18. Joshi SS, Jackson JD, Sharp JG. Comparison of the growth and metastasis of four human intestinal tumor cell line xenografts. Tumour Biol 1989; 10(3): 117-125.
19. Sharp JG. Micrometastases and transplantation. J Hematother 1996; 5(5): 519-524.
20. Traystman MD et al. Comparison of molecular cytokeratin 19 reverse transcriptase polymerase chain reaction (CK19 RT-PCR) and immunocytochemical detection of micrometastatic breast cancer cells in hematopoietic harvests. J Hematother 1997; 6(6): 551-561.
21. Jung R et al. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. Brit J Cancer 1998; 78(9): 1194-1198.